Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, announced on December 15, 2025, the filing of its unaudited interim financial statements as of and for the three-month period ended October 31, 2025. The filings, which include the management’s discussion and analysis (MD&A) and CEO and CFO certifications, are now available on the Company’s profile at www.sedarplus.ca and on its website at https://www.helixbiopharma.com/filings-and-financials/.
The financial reporting provides stakeholders with updated insights into the Company's financial health as it continues to develop its oncology pipeline. Helix is focused on addressing hard-to-treat cancers through innovative therapies. Its lead candidate, Tumor Defense Breaker L-DOS47, is a clinical-stage antibody-enzyme conjugate designed to target CEACAM6-expressing tumors, increasing their sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and serves as the foundation for the Company's next-generation bispecific antibody-drug conjugates (ADCs) currently in discovery.
Beyond L-DOS47, Helix is advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator targeting durable remission in post-transplant leukemia relapse, and GEMCEDA, a first-in-class oral gemcitabine prodrug with bioavailability comparable to intravenous administration, designed to expand treatment options for advanced cancers. These candidates underscore the Company's commitment to developing near-term solutions for patients with limited options.
The filing of interim financial statements is a routine regulatory requirement, but it also signals the Company's ongoing operational progress. As a clinical-stage entity, Helix relies on financial disclosures to maintain transparency with investors and regulators. The news release also includes forward-looking statements regarding the Company's plans and expectations for its pipeline, subject to risks and uncertainties detailed in its periodic reports on SEDAR+.
Helix BioPharma is listed on the Toronto Stock Exchange, OTC Pink, and Frankfurt Stock Exchange. The Company's financial filings and additional information can be accessed via its website or through SEDAR+. The next quarterly update will provide further details on the Company's financial performance and pipeline developments.
